Jan 09, 2023 / 06:30PM GMT
Christopher Thomas Schott - JPMorgan Chase & Co, Research Division - Senior Analyst
Good morning, everybody. I'm Chris Schott from JPMorgan, and it's my pleasure to be introducing Gilead today. From the company, we have a presentation from Dan O'Day, the company's Chairman and CEO. And following that presentation, we'll have a broader Q&A panel with the rest of the management team. So Dan, happy new year. Thanks for joining us, and over to you.
Daniel P. O'Day - Gilead Sciences, Inc. - Chairman & CEO
Thank you, Chris. Good morning, everybody. Terrific to be with all of you today, and it's really great to be back after, gosh, 3 years, right, since we were last here. And I'm really pleased to be with the team up here today. We're going to be focusing on our work for 2023 and beyond. I want to start by thanking Chris and the organizers for the conference for getting us all together. And really, I want to say right up front today, after 3 years, we laid our strategy out about 3 years ago. I can say we've successfully transformed the
Gilead Sciences Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers